Cheong Jit Kong, Zhang Fuquan, Chua Pei Jou, Bay Boon Huat, Thorburn Andrew, Virshup David M
J Clin Invest. 2015 Apr;125(4):1401-18. doi: 10.1172/JCI78018. Epub 2015 Mar 23.
Activating mutations in the RAS oncogene are common in cancer but are difficult to therapeutically target. RAS activation promotes autophagy, a highly regulated catabolic process that metabolically buffers cells in response to diverse stresses. Here we report that casein kinase 1α (CK1α), a ubiquitously expressed serine/threonine kinase, is a key negative regulator of oncogenic RAS-induced autophagy. Depletion or pharmacologic inhibition of CK1α enhanced autophagic flux in oncogenic RAS-driven human fibroblasts and multiple cancer cell lines. FOXO3A, a master longevity mediator that transcriptionally regulates diverse autophagy genes, was a critical target of CK1α, as depletion of CK1α reduced levels of phosphorylated FOXO3A and increased expression of FOXO3A-responsive genes. Oncogenic RAS increased CK1α protein abundance via activation of the PI3K/AKT/mTOR pathway. In turn, elevated levels of CK1α increased phosphorylation of nuclear FOXO3A, thereby inhibiting transactivation of genes critical for RAS-induced autophagy. In both RAS-driven cancer cells and murine xenograft models, pharmacologic CK1α inactivation synergized with lysosomotropic agents to inhibit growth and promote tumor cell death. Together, our results identify a kinase feedback loop that influences RAS-dependent autophagy and suggest that targeting CK1α-regulated autophagy offers a potential therapeutic opportunity to treat oncogenic RAS-driven cancers.
RAS癌基因中的激活突变在癌症中很常见,但难以成为治疗靶点。RAS激活会促进自噬,这是一个高度受调控的分解代谢过程,可在细胞应对各种应激时进行代谢缓冲。在此我们报告,酪蛋白激酶1α(CK1α),一种普遍表达的丝氨酸/苏氨酸激酶,是致癌RAS诱导的自噬的关键负调节因子。CK1α的缺失或药物抑制增强了致癌RAS驱动的人成纤维细胞和多种癌细胞系中的自噬通量。FOXO3A是一种主要的长寿调节因子,可转录调节多种自噬基因,是CK1α的关键靶点,因为CK1α的缺失降低了磷酸化FOXO3A的水平并增加了FOXO3A反应性基因的表达。致癌RAS通过激活PI3K/AKT/mTOR途径增加CK1α蛋白丰度。反过来,CK1α水平的升高增加了核FOXO3A的磷酸化,从而抑制了对RAS诱导的自噬至关重要的基因的反式激活。在RAS驱动的癌细胞和小鼠异种移植模型中,药物性CK1α失活与溶酶体促渗剂协同作用以抑制生长并促进肿瘤细胞死亡。总之,我们的结果确定了一个影响RAS依赖性自噬的激酶反馈回路,并表明靶向CK1α调节的自噬为治疗致癌RAS驱动的癌症提供了潜在的治疗机会。